Overview
- The judge, ruling Tuesday in Lafayette, put Louisiana’s case on hold and left in place the FDA’s 2023 policy that lets certified pharmacies dispense and mail the abortion pill.
- He ordered the FDA to file a status update within six months on its ongoing safety review, which began last year and has been reported delayed until after November.
- Louisiana Attorney General Liz Murrill sued in October to restore in-person pickup, and the judge said the plaintiffs are likely to succeed on the merits when the case resumes.
- Drug makers Danco Laboratories and GenBioPro intervened to defend the 2023 rule, arguing in court filings there is no scientific basis to reverse it.
- Conservative states are pursuing cases against out-of-state prescribers as shield-law states refuse extradition, leaving mail and telehealth access available for patients yet risky for providers.